SEC Form 4 · accession 0001144204-17-009663
DERMA SCIENCES, INC. · DSCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert G Moussa
Director
Period of report
Feb 10, 2017
Accepted (ET)
Feb 16, 2017 · 7:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000892160
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 10, 2017 | M | 4,375 | $6.40 | A | 85,771 | D | |
| Common StockF1 | Feb 10, 2017 | F | 4,000 | $7.00 | D | 81,771 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F2 | $6.40 | Feb 10, 2017 | M | 4,375 | D | Mar 1, 2007 | Feb 22, 2017 | Common Stock | 4,375 | 0 | D |
Explanation of responses
- F1Shares delivered in connection with the cashless exercise of 4,375 options, previously granted pursuant to the issuer's stock option plan, at an exercise price of $6.40, as reported herein.
- F2A total of 35,000 of the options were granted pursuant to the issuer's stock option plan on March 1, 2007. Options for 25% of the shares vested immediately and options for the remaining shares vested at the rate of 25% per year starting on February 22, 2008. The revised total of 4,375 options reflects the issuer's 1-for-8 reverse split effective January 1, 2010.
- F3The options were originally granted in consideration of the reporting person's services to the issuer and without payment of cash.